Human papillomavirus vaccines and prevention of cervical cancer

被引:55
作者
Jansen, KU [1 ]
Shaw, AR [1 ]
机构
[1] Merck & Co Inc, West Point, PA 19486 USA
来源
ANNUAL REVIEW OF MEDICINE | 2004年 / 55卷
关键词
virus-like particle vaccines; vaccine delivery; proof-of-concept; clinical endpoints;
D O I
10.1146/annurev.med.55.091902.103520
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Cervical cancer and precancerous cervical lesions constitute a major problem in women's health. Every year 470,000 cases of cervical cancer are diagnosed worldwide, and about half the women afflicted will die. In the United States alone, similar to14,000 cases of cervical cancer are diagnosed each year despite the availability of screening and access to high-quality gynecological care. With the confirmation that cervical cancer is caused by an infectious agent, human papillomavirus, the possibility of fighting this disease with either prophylactic or therapeutic vaccination arose. This review describes advances in vaccine development and very promising first results for prophylactic vaccination against cervical cancer.
引用
收藏
页码:319 / 331
页数:13
相关论文
共 60 条
  • [1] ABRAMSON AL, 1987, LARYNGOSCOPE, V97, P678
  • [2] Auvinen E, 1997, INT J ONCOL, V11, P1297
  • [3] GENITAL HUMAN PAPILLOMAVIRUS INFECTION IN FEMALE UNIVERSITY-STUDENTS AS DETERMINED BY A PCR-BASED METHOD
    BAUER, HM
    TING, Y
    GREER, CE
    CHAMBERS, JC
    TASHIRO, CJ
    CHIMERA, J
    REINGOLD, A
    MANOS, MM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (04): : 472 - 477
  • [4] Billich Andreas, 2003, Curr Opin Investig Drugs, V4, P210
  • [5] BOETTINGER M, 1997, VACCINE, V15, P1538
  • [6] PROPAGATION OF HUMAN PAPILLOMAVIRUS TYPE-11 IN HUMAN XENOGRAFTS USING THE SEVERE COMBINED IMMUNODEFICIENCY (SCID) MOUSE AND COMPARISON TO THE NUDE-MOUSE MODEL
    BONNEZ, W
    ROSE, RC
    DARIN, C
    BORKHUIS, C
    JENSEN, KLD
    REICHMAN, RC
    [J]. VIROLOGY, 1993, 197 (01) : 455 - 458
  • [7] A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer
    Borysiewicz, LK
    Fiander, A
    Nimako, M
    Man, S
    Wilkinson, GWG
    Westmoreland, D
    Evans, AS
    Adams, M
    Stacey, SN
    Boursnell, MEG
    Rutherford, E
    Hickling, JK
    Inglis, SC
    [J]. LANCET, 1996, 347 (9014) : 1523 - 1527
  • [8] The causal relation between human papillomavirus and cervical cancer
    Bosch, FX
    Lorincz, A
    Muñoz, N
    Meijer, CJLM
    Shah, KV
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2002, 55 (04) : 244 - 265
  • [9] Construction and characterisation of a recombinant vaccinia was expressing human papillomavirus proteins for immunotherapy of cervical cancer
    Boursnell, MEG
    Rutherford, E
    Hickling, JK
    Rollinson, EA
    Munro, AJ
    Rolley, N
    McLean, CS
    Borysiewicz, LK
    Vousden, K
    Inglis, SC
    [J]. VACCINE, 1996, 14 (16) : 1485 - 1494
  • [10] Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: Correlation with competitive radioimmunoassay titer
    Brown, DR
    Bryan, JT
    Schroeder, JM
    Robinson, TS
    Fife, KH
    Wheeler, CM
    Barr, E
    Smith, PR
    Chiacchierini, L
    DiCello, A
    Jansen, KU
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (09) : 1183 - 1186